{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:25:13Z","timestamp":1790220313313,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.schres.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T13:20:24Z","timestamp":1481289624000},"page":"145-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial"],"prefix":"10.1016","volume":"184","author":[{"given":"Reza","family":"Rahmanzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Eftekhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-reza","family":"Khodaei Ardakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Rahmanzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Taghi","family":"Joghataei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2016.12.002_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archgenpsychiatry.2010.114","article-title":"Altered expression of regulators of the cortical chloride transporters NKCC1 and KCC2 in schizophrenia","volume":"68","author":"Arion","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2016.12.002_bb0010","first-page":"260","article-title":"On the neurobiology of hallucinations","volume":"34","author":"Boksa","year":"2009","journal-title":"J. Psychiatry Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2016.12.002_bb0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/schbul\/21.4.567","article-title":"Conventional antipsychotic medications for schizophrenia","volume":"21","author":"Dixon","year":"1995","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2016.12.002_bb0020","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1111\/j.1528-1167.2012.03654.x","article-title":"Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy","volume":"54","author":"Eftekhari","year":"2013","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.schres.2016.12.002_bb0025","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.neuropharm.2011.05.011","article-title":"Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia","volume":"62","author":"Grace","year":"2012","journal-title":"Neuropharmacology"},{"issue":"30","key":"10.1016\/j.schres.2016.12.002_bb0030","doi-asserted-by":"crossref","first-page":"11088","DOI":"10.1523\/JNEUROSCI.1234-11.2011","article-title":"Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia","volume":"31","author":"Hyde","year":"2011","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.schres.2016.12.002_bb0035","first-page":"365","article-title":"Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects","volume":"29","author":"Kinon","year":"1993","journal-title":"Psychopharmacol. Bull."},{"issue":"12","key":"10.1016\/j.schres.2016.12.002_bb0040","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","article-title":"The diuretic bumetanide decreases autistic behaviour in five infants treated during 3months with no side effects","volume":"99","author":"Lemonnier","year":"2010","journal-title":"Acta Paediatr."},{"issue":"2","key":"10.1016\/j.schres.2016.12.002_bb0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/WNF.0000000000000136","article-title":"Treating schizophrenia with the diuretic bumetanide: a case report","volume":"39","author":"Lemonnier","year":"2016","journal-title":"Clin. Neuropharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416305606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416305606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T03:51:30Z","timestamp":1536205890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416305606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":9,"alternative-id":["S0920996416305606"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.12.002","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}